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Abstract: The pro-apoptotic Bcl-2 family member Bad acts as a sensitizer in intrinsic apoptosis by in-
activating anti-apoptotic members through heterodimer ormation. Bad has been shown to contribute to
tumorigenesis including lymphoma formation in humans and mice through alteration in expression and/or
functional status. Here, its immunohistochemical expression was analyzed in canine non-neoplastic and
lymphoma tissues using tissue microarrays. Bad was expressed in the cytoplasm of a wide range of
non-neoplastic tissues, especially epithelial cells. Non-neoplastic lymph nodes displayed weak immunos-
taining in the follicular germinal centers only. Immunoblotting supported these observations, but also
revealed presence of nonspecific labeling in some organs. Twenty-nine of 81 lymphomas (35.8%) displayed
moderate to strong immunohistochemical Bad labeling, and signal intensity was significantly enhanced
in lymphomas (especially B-cell and double negative) compared to non-neoplastic lymph nodes. These
findings suggest the occurrence of altered Bad expression in a portion of the lymphomas and warrant
further investigations of the functional status, the involvement of partner proteins and a possible im-
pact of Bad on prognosis in canine lymphoma. Das pro-apoptotische Bcl-2-Familienmitglied Bad wirkt
als Sensibilisator im intrinsischen apoptotischen Signalweg und inaktiviert anti-apoptotische Partnerpro-
teine durch Heterodimerbildung. Eine veränderte Expression und/oder Funktion von Bad spielt eine
Rolle in der Tumorgenese beim Menschen und bei der Maus. In der vorliegenden Studie wurde mit-
tels Immunhistochemie und Tissue Microarrays die Expression von Bad in kaninen nicht-neoplastischen
Geweben und kaninen Lymphomen untersucht. Bad wurde im Zytoplasma von zahlreichen nichtneo-
plastischen Geweben, insbesondere in Epithelzellen, nachgewiesen. Nichtneoplastische Lymphknoten
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Einfluss von Bad auf die Prognose von kaninen Lymphomen.
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Immunohistochemical expression study of pro-apoptotic BH3-only 
protein Bad in canine non-neoplastic tissues and canine 
lymphomas 
Abstract 
The BH3-only protein Bad is a pro-apoptotic Bcl-2 family member that acts as a sensitizer in 
intrinsic apoptosis by inactivating anti-apoptotic members through heterodimer formation. 
Bad has been shown to contribute to tumorigenesis including lymphoma formation in humans 
and mice through alteration in expression and/or functional status. Here, its 
immunohistochemical expression was analyzed in canine non-neoplastic and lymphoma 
tissues using tissue microarrays. Bad was expressed in the cytoplasm of a wide range of 
non-neoplastic tissues, especially epithelial cells. Non-neoplastic lymph nodes displayed 
weak immunostaining in the follicular germinal centers only. Immunoblotting supported these 
observations, but also revealed presence of non-specific labeling in some organs. Twenty-
nine of 81 lymphomas (35.8%) displayed moderate to strong immunohistochemical Bad 
labeling, and a significant expression increase was found in lymphomas (especially B-cell 
and double negative) compared to non-neoplastic lymph nodes. These findings warrant 
further investigations of the functional status, the involvement of partner proteins and a 
possible impact of Bad on prognosis in canine lymphoma. 
 
Key words 
Bad; Bcl-2 family; dog; immunohistochemistry; lymphoma; protein expression; tissue 
microarray (TMA); western blot 
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Introduction 
Apoptosis is essential for normal development and tissue homeostasis and protects against 
diseases including cancer.3 Several members of the Bcl-2 family proteins, which are critical 
regulators of intrinsic apoptosis, have been assigned either oncogenic or tumor suppressor 
properties.2 The pro-apoptotic BH3-only subgroup member Bad (Bcl-XL/Bcl-2 associated 
death promoter) acts as a sensitizer early in the course of intrinsic apoptosis by binding and 
neutralizing its anti-apoptotic partners Bcl-2, Bcl-XL and Bcl-w.1,16 This binding is inhibited by 
phosphorylation of Bad at conserved serine residues which leads to the inactivation of Bad 
through sequestration by cytosolic 14-3-3 proteins.4,11,18 
Ablation of Bad in mice induced diffuse large B-cell lymphomas10 and loss of Bad expression 
was observed in spontaneous epidermal neoplasms in humans.13 Increased levels of 
phosphorylated Bad were found in follicular lymphomas and colorectal carcinomas.7,17 
Publicly available immunohistochemical data indicate that Bad is widely expressed in normal 
human organs.8,12 In some tissues including lymphatic organs and a limited number of 
lymphoma cell lines and lymphoma samples, expression levels of Bad appeared to be low or 
even absent.8,12 
Due to the apparent lack of canine data, the aim of the present study was to assess the 
expression of Bad in non-neoplastic tissues and lymphomas in this species by means of 
immunohistochemistry. 
Material and Methods 
Canine tissues and cultured cells 
Tissues. Tissue microarrays (TMAs) containing archival canine non-neoplastic organs (Table 
1) were available from a previous study.14 In addition, normal, non-neoplastic mandibular 
lymph node samples were available; they comprised a TMA containing six to ten 1.2 mm 
cores from each of 18 dogs and a multi-block containing larger lymph node probes from 
seven further dogs. Selected normal tissues were freshly collected and snap-frozen for 
western blot analysis. TMAs containing four cores of 0.6 mm diameter each from 90 cases of 
canine lymphoma immunophenotyped and classified were available from previous 
studies.5,14 Representativeness of cores was assessed on consecutive sections labeled with 
HE and with immunohistochemical CD3 and CD79αcy markers as described.14 
Canine T-cell lymphoma CL-1 cells. The cells were cultured in RPMI 1640 medium with 
stable glutamine (E15-885, PAA Laboratories, Pasching, Austria) supplemented with fetal 
calf serum 10% (BioConcept Ltd., Allschwil, Switzerland) and penicillin/streptomycin 1% 
(Gibco BRL Life Sciences, Basel, Switzerland) under standard conditions. Pellets were 
constructed for immunohistochemistry as described using cells fixed for 24 h in 4% 
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formaldehyde.6 For western blot analysis, the cells were washed with ice cold PBS and 
pelleted in 15 ml tubes at 6000 g for 2 min at 4 °C. The supernatant was discarded, the pellet 
was resuspended in PBS, and centrifuged at 16 000 g for 1 min at 4 °C in a 1.5 ml 
Eppendorf tube. The pelleted cells were lysed in ice-cold lysis buffer (20 mM Tris, 100 mM 
NaCl, 1 mM EDTA, 0.5% Triton X) supplemented with protease inhibitors (1 mM PMSF, 0.3 
µM Aprotinin, 0.5% Leupeptin, 0.01% Pepstatin-A), centrifuged at 16 000 g for 15 min at 4 °C 
and the supernatant was stored at 4 °C until further processing. 
Immunohistochemistry 
Sections (2 µm) were mounted on positively charged glass slides and immunostained in a 
Discovery XT autostainer (Ventana Medical Systems, Inc., Tucson AZ, USA) using the CC1 
antigen retrieval program and the monoclonal antibody 1541-1 against human Bad 
(Epitomics, Burlingame CA, USA) in a 1:1500 dilution. The immunohistochemical procedure 
as well as the antibody selection and validation process, which relied on the use of canine 
recombinant Bad protein and of UV-irradiated canine keratinocytes, are extensively 
described in the supplementary material. Negative controls using 1% BSA in PBS instead of 
the primary antibody were carried out for each section. All tissues were scored according to 
the cytoplasmic immunohistochemical signal intensity as follows: 0 = signal absent, 1 = 
weak, 2 = moderate, 3 = strong signal. The score assigned to a given cell type corresponded 
to the signal intensity displayed by more than 50% of the cells. The reported final scores for 
each cell type were calculated as mean values of two independent readings by one author 
(MD). For a lymphoma case to be scored, presence of at least two properly labeled 
representative cores with more than 50% of the core well preserved was required. A mean 
score for all cores of each tumor was calculated. The immunohistochemical signal intensity 
scores of B-cell, T-cell, and double negative (DN) lymphoma immunophenotypes and of the 
non-neoplastic lymph nodes (n=26) were compared statistically using the non-parametric 
Kruskal-Wallis-rank sum test and Dunn’s post hoc z-value test. P-values lower than 0.05 (z-
values >2.638) were considered to indicate statistical significance. Analyses were performed 
using SPSS (Version 20, SPSS Inc, Chicago IL, USA). 
Western Blots 
Tissue pieces (approx. 200 mg) were thawed, lysed in 1.5 ml lysis buffer (15 mM HEPES pH 
7.5, 15 mM NaCl, 60mM KCl, 0.27 M sucrose, 2 mM EDTA pH 8.0, 1% Triton-X, protease 
inhibitors as above) using a pestle, and centrifuged three times at 16 000 g for 15 min at 4 
°C. Lysates of tissues (containing 100 µg of protein as determined with the Bradford method) 
and of CL-1 cells (18 µg, measured using a NanoDrop-1000 (Thermo Fisher Scientific, 
Wilmington, DE, USA)) were loaded with 4x SDS loading buffer (0.25 M Tris/HCl pH 6.8, 8% 
SDS, 10% glycerol, 0.02% bromphenol blue, 10% β-mercaptoethanol) on a 12% 
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polyacrylamide gel and blotted (Fastblot B43, Biometra GmbH, Göttingen, Germany) onto a 
PVDF membrane (Immobilon-P Transfer Membrane, Millipore Corporation, Billerica MA, 
USA). After blocking with 3% BSA in TBST (Dako Wash Buffer 10x, Dako Schweiz AG, Baar, 
Switzerland), membranes were incubated with antibody 1541-1 (Epitomics) diluted 1:5000, 
washed with TBST, incubated with a horseradish peroxidase-conjugated polyclonal goat-
anti-rabbit antibody (Jackson ImmunoResearch, Soham, UK) diluted 1:10 000, washed, 
incubated with LumiGLO (Kirkegaard & Perry Laboratories Inc., Gaithersburg MD, USA) and 
developed on an enhanced chemiluminiscence film (Amersham Hyperfilm ECL, GE 
Healthcare Limited, Buckinghamshire, UK). For negative control, 1% BSA in TBST was used 
instead of the primary antibody. 
Results 
This study analyzed immunohistochemically the expression of Bad in canine non-neoplastic 
tissues and lymphomas assembled in TMAs using an extensively validated monoclonal 
antibody (see Supplementary Material). The results were partially corroborated by western 
blot analyses. 
Non-neoplastic tissues 
The immunohistochemical signal (Table 1, Figs. 1 to 11) was limited to the cell cytoplasm. It 
was either diffusely homogeneous or coarsely granular, except for cells of the exocrine 
pancreas and adrenal medulla, where it appeared as well demarcated, large, intensely 
labeled granules, or as large, empty vesicles, respectively. Several organs and cell types 
displayed weak to moderate labeling intensities. A strong labeling was generally present in 
exocrine pancreas cells (Fig. 4), renal proximal tubular epithelium (Fig. 5), spermatids (Fig. 
7) and the tracheal epithelium. Labeling was completely absent from superficial epidermal 
cells (granular and cornified layer), fibrous tissues, and striated muscles (Fig. 9), and from all 
negative controls. Cores from different dogs often displayed small differences in signal 
intensities (Table 1). Rare cell types with interindividual differences greater than one score 
point included small intestinal enterocytes and prostatic epithelial cells. In non-neoplastic 
lymph nodes immunohistochemical labeling of lymphocytes was in general mainly restricted 
to germinal center lymphocytes (score 1), while mantle and interfollicular zones were 
negative (Figs. 10a and 10b). 
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Table 1. Immunohistochemical detection of Bad in non-neoplastic canine tissues (continued next 
page). 
Organ	  /	  tissue	   Cell	  type	   Signal	  intensitya	   Signal	  patternb	  
Epidermis	   Basal	  cell	  layer	   1-­‐2	   DH	  
	   Spinous	  layer	   1	   DH	  
	   Granular	  &	  cornified	  layer	   0	   -­‐	  
Fibrous	  tissue	   Fibrocytes	   0	   -­‐	  
Skeletal	  muscle	   Myocytes	   0	   -­‐	  
Smooth	  muscle	   Myocytes	   0-­‐1	   DH	  
Heart	   Myocardium	   0-­‐1	   DH	  
Vessels	   Endothelium	   1	   DH	  
Trachea	  &	  lung	   Respiratory	  epithelium	   2-­‐3	   DH	  
	   Chondrocytes	   1	   DH	  
	   Pneumocytes	   0-­‐1	   DH	  
	   Alveolar	  macrophages	   1-­‐2	   DG	  
Salivary	  glands	   Secretory	  cells	   0-­‐1	   DH	  
Esophagus	   Epithelium	   1	   DH	  
Stomach	   Parietal	  cells	   2	   DG	  
	   Chief	  cells	   1	   DH	  
Intestine	   Enterocytes	  (villi	  &	  crypts)	   1-­‐3	   DG	  
Liver	   Hepatocytes	   1-­‐2	   DG	  
Pancreas	   Exocrine	  cells	   2-­‐3	   LG	  
	   Islets	  of	  Langerhans	   1	   DG	  
Kidney	   Glomeruli	   0-­‐1	   DH	  
	   Proximal	  tubules	   2-­‐3	   DG	  
	   Distal	  tubules	   1-­‐2	   DG	  
Bladder	   Epithelium	   1	   DH	  
Ovary	   Germinal	  epithelium	   1-­‐2	   DH	  
	   Corpus	  luteum	   2	   DH	  
Uterus	   Endometrium	   1-­‐2	   DH	  
Vagina	   Epithelium	   1-­‐2	   DH	  
Mammary	  gland	   Epithelium	   1	   DH	  
Prostate	  gland	   Epithelium	   0-­‐2	   DH	  
Testis	   Spermatogonia	   1-­‐2	   DG	  
	   Spermatocytes	   2-­‐3	   DG	  
	   Spermatids	   3	   DG	  
	   Spermatozoa	   1-­‐2	   DG	  
	   Sertoli	  cells	   1-­‐2	   DG	  
	   Leydig	  cells	   1	   DG	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Table 1. (continued) 
Spleenc	   Red	  pulp	   0-­‐1	   DH	  
Tonsil	  &	  lymph	  node	   Follicular	  germinal	  center	   1-­‐2	   DH	  
	   Mantle	  zone	   0-­‐1	   DH	  
	   Interfollicular	  regions	   0	   -­‐	  
	   Plasma	  cells	   2-­‐3	   DH	  
Thymus	   Cortex	  and	  medulla	   0-­‐1	   DH	  
Bone	  marrow	   Myeloid	  precursors	   0-­‐1	   DH	  
	   Erythrocyte	  precursors	   2-­‐3	   DH	  
	   Megakaryocytes	   0-­‐1	   DH	  
Adrenal	  gland	   Cortex	   1	   DH	  
	   Medulla	   2	   V	  
Thyroid	  gland	   Follicular	  epithelium	   1-­‐2	   DG	  
Parathyroid	  gland	   Epithelium	   1-­‐2	   DG	  
Cerebral	  cortex	   Large	  neurons	   1-­‐2	   DH	  
	   Neuropil	   0-­‐1	   DH	  
	   Neuroglia	   0-­‐1	   DH	  
	   Axons	  in	  white	  matter	   2	   DH	  
Cerebellum	   Purkinje	  cells	   1-­‐2	   DH	  
	   Axons	  in	  granular	  layer	   2	   DH	  
Spinal	  cord	   Neurons	   1	   DH	  
	   Neuroglia	   0-­‐1	   DH	  
	   Neuropil	   0-­‐1	   DH	  
	   Ependyme	   1-­‐2	   DH	  
a	  Signal	  intensity	  score:	  0	  =	  absent;	  1	  =	  weak;	  2	  =	  moderate;	  3	  =	  strong.	  A	  range	  of	  score	  values	  denotes	  interindividual	  differences.	  
b	  Cytoplasmic	  signal	  distribution:	  DH=diffusely	  homogeneous;	  DG=diffusely	  granular;	  LG=large	  demarcated	  granules;	  V=vesicular	  
c	  White	  pulp	  not	  present	  in	  available	  cores.	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Figures 1-11. Immunohistochemical Bad labeling of non-neoplastic canine tissues (each from a 
different dog). The immunohistochemical signal was limited to the cytoplasm. Anti-Bad antibody 1541-
1, detection with Omni-UltraMap, hematoxylin counterstain. Figure 1. Stomach. Gastric mucosa with 
granularly labeled parietal cells (signal intensity score 2) and homogeneously labeled chief cells (score 
1). Figure 2. Small intestine. Villi with granularly labeled enterocytes (score 3). Figure 3. Liver. 
Hepatocytes with granular labeling (score 2). Figure 4. Pancreas. Strongly labeled demarcated 
granules in exocrine cells (score 3) and weakly labeled islets of Langerhans (score 1). Figure 5. 
Kidney. Renal cortex with granularly labeled proximal tubuli (score 3), granularly labeled distal tubuli 
(score 2), and homogeneously labeled glomeruli (score 1). Figure 6. Prostate gland. Homogeneously 
labeled epithelium (score 1). Figure 7. Testis. Slightly labeled spermatogonia and Sertoli cells (score 
1), granularly labeled spermatocytes (score 2), homogeneously labeled spermatids (score 3), slightly 
labeled spermatozoa (score 1), and slightly labeled Leydig’s cells (score 1). Figure 8. Thyroid gland. 
Granularly labeled follicular epithelium (score 2). (Continued next page.) 
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(Figure legend continued:) Figure 9. Skeletal muscle. Unlabeled myocytes. Figure 10a. Lymph node. 
Weakly labeled germinal center lymphocytes, and unlabeled mantle zone and interfollicular region 
lymphocytes. Figure 10b. Lymph node, higher magnification. Germinal center lymphocytes with 
homogeneous labeling (score 1). Figure 11. Tonsil. Homogeneously labeled plasma cells (score 2) 
and unlabeled lymphocytes. 
 
 
Western blots run for Bad with lysates of selected non-neoplastic tissues to test the reliability 
of immunohistochemistry (Fig. 12) showed, in general, overall intensities matching well with 
the immunohistochemical signals. However, kidney, pancreas, and liver lysates showed, 
besides the expected single band at 21 kDa or double band at 21 and 18 kDa, one or two 
additional, prominent, likely non-specific bands at 40 and 50 kDa. In contrast, the major 
product labeled by the antibody in extracts of normal lymphatic tissues and testis had the 
expected size. 
 
 
 
 
Figure 12. Western blot for Bad with 
antibody 1541-1 in non-neoplastic 
tissue lysates of indicated organs. 
Distinct bands compatible with Bad at 
21 kDa and partly also at 18 kDa are 
present in liver, kidney, tonsil, lymph 
node, testis and pancreas lysates; 
liver, kidney and pancreas lysates 
show additional prominent bands at 
40 and/or 50 kDa. 
Figure 13. Western blot for Bad with 
antibody 1541-1 in CL-1 lymphoma 
cell lysates. Two bands of expected 
size are very prominently labeled. 
 
Lymphomas 
Bad immunohistochemistry of CL-1 lymphoma cells resulted in a generalized, marked 
cytoplasmic signal (Fig. 14), while a western blot showed exclusive labeling of a double band 
of 21 kDa (major product) and 18 kDa (Fig. 13) supporting specificity of the antibody. 
Neoplastic cells of the 81 cases fulfilling the inclusion criteria predominantly displayed a 
diffusely homogeneous cytoplasmic signal, with a superimposed granulated pattern observed 
in a few cases. Overall, the lymphoma cases showed scores ranging from 0 to 3 (Figs. 15 to 
18) with a mean value of 1.08, a median value of 1.00 and a standard deviation of 0.73. The 
labeling intensity varied very little within cores, while in about 50% of the lymphoma cases a 
slight inter-core variability of up to maximally one scoring point (in one single case two 
points) was noted. Table 2 lists the scoring results of the lymphoma cases grouped 
according to immunophenotype and most frequent subtypes, as well as of all normal lymph 
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node tissues available on TMAs. While most non-neoplastic lymph nodes (25 of 26, 96.2%) 
displayed an overall signal intensity score ≤ 1, this applied to only 52 of 81 (64.2%) 
lymphoma cases. The remaining 29 cases (comprising 17 B-cell, 4 T-cell and 8 DN 
lymphomas) showed scores > 1. Among B-cell lymphomas, the heterogeneous group with 
less common subtypes and not classifiable lymphomas displayed higher signal intensities 
than the other groups. One-way analysis of variance with the Kruskal-Wallis rank sum test 
showed a statistically significant difference in the labeling intensity between non-neoplastic 
lymph nodes and the whole group of lymphomas (p<0.001). A Dunn’s post hoc z-value test 
revealed a statistically significant difference between non-neoplastic lymph nodes and B-cell 
lymphomas (z=3.602, p=0.002), between non-neoplastic lymph nodes and DN lymphomas 
(z=4.557, p=0.001) and between T-cell lymphomas and DN lymphomas (z=3.739, p=0.001). 
 
 
 
 
Figure 14-18. Immunohistochemical Bad labeling in canine lymphoma. Anti-Bad antibody 1541-1, 
detection with Omni-UltraMap, hematoxylin counterstain. Figure 14. Formalin-fixed and paraffin wax-
embedded CL-1 lymphoma cells displaying a strong cytoplasmic signal. Inset: Same cells at higher 
magnification. Figure 15. Lymphoma, case L53. Neoplastic cells showing signal intensity score 0. 
Figure 16. Lymphoma, case L7. Neoplastic cells showing score 1. Figure 17. Lymphoma, case L15. 
Neoplastic cells showing score 2. Figure 18. Lymphoma, case L88. Neoplastic cells showing score 3. 
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Table 2. Immunohistochemical detection of Bad in canine lymphomas and non-neoplastic lymph 
nodes. 
Lymphoma	  subtype	  according	  to	  indicated	  
classification	  scheme	  
Total	  
number	  of	  
cases	  
Number	  of	  	  cases	  with	  indicated	  mean	  Bad	  
signal	  intensity	  scorea	  
Revised	  Kiel	   REAL-­‐WHO	   	   0	   ≤1	   ≤2	   ≤3	  
B-­‐Immunophenotype	  (n=48)	   	   	   	   	   	   	  
Centroblastic	  monomorphic	   Diffuse	  large	  B-­‐cell	   10	  (12.4%)	   1	  (1.2%)	   8	  (9.9%)	   1	  (1.2%)	   0	  
Centroblastic	  polymorphic	   Diffuse	  large	  B-­‐cell	   15	  (18.5%)	   0	   13	  (16.0%)	   2	  (2.5%)	   0	  
Marginal	  zone	   Marginal	  zone	   10	  (12.4%)	   1	  (1.2%)	   5	  (6.2%)	   4	  (5.0%)	   0	  
Other	  subtypes	  /	  not	  
classifiable	  
	  
	   13	  (16.0%)	   0	   3	  (3.7%)	   7	  (8.6%)	   3	  (3.7%)	  
T-­‐Immunophenotype	  (n=23)	   	   	   	   	   	   	  
Pleomorphic	  (various	  sizes)	   Peripheral	  T-­‐cell	  not	  
otherwise	  specified	  
12	  (14.8%)	   3	  (3.7%)	   8	  (9.9%)	   1	  (1.2%)	   0	  
Other	  subtypes	  /	  not	  
classifiable	  
	  
	   11	  (13.6%)	   2	  (2.5%)	   6	  (7.4%)	   3	  (3.7%)	   0	  
Double-­‐Negative	  
Immunopheno-­‐type	  (n=10)	  
	  	   	   	   	   	   	  
High-­‐grade,	  medium	  sized	   	   5	  (6.2%)	   0	   0	   3	  (3.7%)	   2	  (2.5%)	  
Other	  subtypes	  /	  not	  
classifiable	  
	   5	  (6.2%)	   0	   2	  (2.5%)	   2	  (2.5%)	   1	  (1.2%)	  
Total	  lymphoma	  cases	   	   81	  (100%)	   7	  (8.6%)	   45	  (55.6%)	   23	  (28.4%)	   6	  (7.4%)	  
Non-­‐neoplastic	  lymph	  nodes	   	   26	  (100%)	   5	  (19.2%)	   20	  (77.0%)	   1	  (3.8%)	   0	  
a	  Signal	  intensity	  score:	  0	  =	  absent;	  1	  =	  weak;	  2	  =	  moderate;	  3	  =	  strong;	  a	  mean	  of	  all	  available	  cores	  was	  calculated	  for	  each	  case.	  
 
Discussion 
The present study analyzed the expression of Bad protein in canine lymphomas. Since 
ablation of Bad was purported to promote lymphoma development in mice,10 a decreased 
Bad expression in canine lymphoma compared to non-neoplastic lymph nodes was 
considered as a possible outcome. However, no such finding was observed here. Instead, a 
considerable fraction of the lymphomas (35.8%) showed higher Bad expression than non-
neoplastic lymphocytes, a difference that was statistically significant for B-cell and DN 
lymphomas, possibly indicating enhanced apoptotic signaling in the affected tumors. These 
findings contrast with the results of previous human studies showing little or no Bad 
expression in seven lymphoma and leukemia cell lines8 and in 20 of 22 malignant 
lymphomas.12 However, another report indicated higher Bad expression levels in diffuse 
large B-cell lymphomas compared to follicular and mantle cell lymphomas.15 Unfortunately, 
the number of cases in the present canine study was too small to assess statistical 
differences between subtypes. Moreover, there was no relationship between Bad expression 
and markers of apoptotic activity such as cleaved caspase-3 or cleaved lamin A in our 
material (unpublished data). This can be considered as an additional argument against a 
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prominent role of Bad in the genesis of canine lymphoma. Since execution of intrinsic 
apoptosis is thought to depend on stoichiometric interactions of Bcl-2 family members, the 
role of this protein might be more precisely assessed with a comprehensive approach 
probing the whole family. 
Two reports indicate the presence of phosphorylated Bad in human follicular and cutaneous 
T-cell lymphomas.17,19 Thus, it might be of interest to determine the functional status of Bad 
in future studies, which was omitted here due to failure to find a suitable phosphorylation 
specific antibody (data not shown). However, the diffusely homogeneous signal observed in 
the canine tumors suggests that the enhanced signal may be due to an increase of inactive 
hyperphosphorylated Bad, which is sequestered in the cytoplasm by the scaffold protein 14-
3-3. An involvement of Bad has been hypothesized in the development of chemotherapy 
resistance in human diffuse large B-cell lymphomas found to overexpress the isoform 14-3-
3ζ.9 
The other main part of this investigation was the analysis of Bad expression in non-
neoplastic tissues. Western blot and immunohistochemical data indicate that Bad is 
expressed in the cytoplasm of a wide range of normal canine cell types. This is consistent 
with investigations of human tissues.8,12 However, western blot results indicate that the 
immunohistochemical findings in this broad tissue collection should be interpreted with 
caution, since in some organs, such as liver, kidney and pancreas, additional non-specific 
bands were present. There is no reported evidence for homodimerization of Bad,18 and the 
reducing conditions of the SDS-PAGE used here should have separated heterodimers as 
well. Thus, the marked immunohistochemical signal observed in these three organs has a 
major non-specific component. Interestingly, the immunohistochemical labeling pattern in the 
exocrine pancreas cells clearly differed from the either diffusely homogeneous or diffusely 
granular pattern observed in most other cell types. In summary, our data show the 
importance of validating antibodies with respect to their reactivity with the specifically 
targeted tissue or cell type. Specific immunohistochemical labeling of lymphomas in this 
study is supported by the lack of non-specific bands in lysates of non-neoplastic lymphatic 
tissues and, notably, of CL-1 lymphoma cells. However, validation by western blot is strongly 
advised for future prospective studies. 
In general, similar to previous human studies, normal epithelial cells displayed a stronger 
signal than mesenchymal cells.8,12 Findings in several mesenchymal tissues including all 
types of musculature differed to some extent between human studies, thus hampering the 
interpretation of the canine data for these cell types. In canine non-neoplastic lymph nodes, a 
weak to moderate immunohistochemical signal was mainly observed in the cytoplasm of 
germinal center lymphocytes, while mantle and interfollicular zone lymphocytes were 
negative, as previously observed by Kitada and colleagues.8 The Protein Atlas12 indicates a 
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weak to moderate signal in lymphatic tissue depending on the antibody used. Common 
explanations for discrepancies between studies include use of different antibodies targeting 
different epitopes and even of different protocols, the occurrence of different isoforms, and 
differences in tissue fixation and processing. Further reasons, possibly applicable here, 
include interspecies differences, inter-individual variability, the small amounts of tissue 
provided by TMAs and non-specific antibody binding in certain tissues. 
In conclusion, the present study showed that the pro-apoptotic Bcl-2 family member Bad is 
expressed in a wide range of normal canine tissues. Our findings indicate that the results of 
immunohistochemical studies should be interpreted with great caution and that accurate 
validation, e.g. through western blotting as in this study, is crucial to rule out non-specific 
cross-reactions. Expression levels of Bad were generally low in non-neoplastic canine 
lymphocytes, but they were increased in a portion of the lymphomas examined. The 
significance of this finding is unknown and further investigation of the functional state of Bad, 
involved partner proteins and a possible impact on prognosis is required. 
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Supplementary material 
 
Selection and validation of a commercially available antibody for 
immunohistochemical detection of Bad in canine tissues 
 
Antibody selection  
Five commercially available antibodies against human or murine Bad (Table S1) were tested 
for cross-reactivity with canine Bad by western blotting and immunohistochemistry against 
fusion proteins consisting of N-terminal Glutathione-S-Transferase (GST, 27 kDa) and canine 
Bad (18 kDa) as well as other canine apoptosis-related proteins expressed in bacteria. In a 
western blot using canine GST-Bad, monoclonal rabbit antibody 1541-1 (Epitomics), which 
recognizes an N-terminal epitope of human Bad, labeled three major bands at 45, 35 and 25 
kDa (Fig. S1a, left panel). The top band represents full-length GST-Bad, while the lower 
bands represent degradation products. In contrast, the antibody showed no reaction with 
lysates from bacteria expressing GST alone or GST-conjugated canine p53 or GST-
conjugated canine Noxa. Polyclonal rabbit antibody JM-3030-100 (MBL International), which 
was raised against purified full-length murine Bad protein, labeled the 45 and 35 kDa bands 
of GST-Bad equally strongly (Fig. S1a, right panel). This antibody displayed no reaction in 
western blots with the other canine GST fusion proteins (data not shown). Polyclonal rabbit 
antibody HPA028185 (Sigma-Aldrich) labeled the 45 and 35 kDa bands only weakly and 
showed no reaction with the other canine GST fusion proteins (data not shown). No signal 
was detectable in western blots with polyclonal rabbit antibody NBP1-19451 (Novus 
Biologicals) or monoclonal mouse antibody sc-8044 (Santa Cruz). These results were 
confirmed using immunohistochemistry with an array of formalin-fixed and paraffin wax-
embedded bacteria expressing various canine GST-fusion proteins (Figs. S1b-e). 
Monoclonal rabbit antibody 1541-1 (Epitomics) displayed a strong signal against the GST-
Bad core, but showed no reactivity towards other GST fusion proteins (Fig. S1c). Polyclonal 
rabbit antibody JM-3030-100 (MBL International) showed a weak specific signal for GST-Bad 
(Fig. S1d). The remaining three antibodies labeled several GST fusion proteins with 
moderate intensity without labeling GST-Bad more strongly under any of the conditions 
tested, and were thus considered unspecific (Fig. S1e and data not shown).  
In summary, antibody 1541-1 was considered the best reagent based on its intense, specific 
labeling of canine GST-Bad in both western blots and immunohistochemistry, and was 
selected for further analysis.  
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Figure S1. Evaluation of commercially available antibodies cross-reactivity and specificity for canine 
Bad using glutathione-S-transferase (GST) fusion proteins. Figure S1a. Western blot against 
indicated canine GST fusion proteins using antibody 1541-1 (left panel), and antibody JM-3030-100 
(right panel). Figures S1b-e. Immunohistochemistry using bacterial pellet array containing formalin-
fixed, paraffin wax-embedded pelleted bacteria expressing canine GST fusion proteins. Figure S1b. 
Array design; Figure S1c. Immunohistochemistry with antibody 1541-1; only bacteria expressing 
GST-Bad are labeled; Figure S1d. Immunohistochemistry with antibody JM-3030-100; only bacteria 
expressing GST-Bad are weakly labeled; Figure S1e. Immunohistochemistry with antibody 
HPA028185; bacteria expressing various GST fusion proteins are unspecifically weakly labeled. 
Detection with Omni-UltraMap or RedMap, hematoxylin counterstain. 
 
 
Validation of antibody 1541-1 
A protocol was developed for the immunohistochemical detection of endogenous levels of 
Bad in canine cells using antibody 1541-1. Since the amount of Bad was expected to change 
in the course of intrinsic apoptosis, the antibody was tested with formalin-fixed and paraffin 
wax-embedded canine keratinocytes following UV-light irradiation (100 mJ). Most of the cells 
underwent cell death morphologically compatible with apoptosis and with extensive presence 
of cleaved caspase-3 (data not shown) within 24 h of treatment. Samples of each collection 
time were examined with immunohistochemistry and western blot (Figs. S2 and S3). 
Non-irradiated control cells displayed a moderate degree of labeling with a finely stippled 
cytoplasmic distribution (Fig. S2a). In cells harvested at 30 minutes and 4 h post irradiation 
(p.i.), a mild diffuse increase of signal intensity compared to non-irradiated cells was 
observed (Figs. S2b and S2c). In addition, at 4 h p.i., single cells showing early signs of 
apoptosis were intensely labeled. At 8 h after irradiation, the intensity of the 
immunohistochemical signal was in most cells similar to the control sample, but an 
increasing number of cells, including some with early morphological signs of apoptosis such 
as nuclear swelling and membrane blebbing showed a marked perinuclear signal (Fig. S2d). 
Other apoptotic cells displayed a very weak labeling. At 12 h p.i., about two thirds of the 
keratinocytes had undergone apoptosis and showed weak or no labeling (Fig. S2e). The 
signal in the remaining viable cells was weak to moderate with a diffuse cytoplasmic to 
perinuclear distribution. At 24 h p.i., the signal had further decreased in intensity and was 
present as weak perinuclear labeling in the cells that had remained intact (Fig. S2f). A 
western blot using materials collected in the same experiment showed presence of a major 
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band at 21 kDa in all samples and of a moderate to weak band at 18 kDa, which almost 
disappeared at 12 h and 24 h p.i. (Fig. S3a, upper panel). This likely represents the 
previously described double band of hyperphosphorylated (upper band) and non- or 
hypophosphorylated Bad (lower band).18 The identity of the 21 kDa band as canine Bad was 
confirmed in a western blot using antibody JM-3030-100 (data not shown). The sum of the 
signal intensities of both Bad-specific bands, relative (antibody 1541-1) to the β-actin band as 
a loading control (Fig. S3a, lower panel), indicates an initial increase in Bad expression up to 
4-8 h, followed by a steady decrease through 12-24 h after UV-irradiation (Fig. S3b).  
In conclusion, these results indicate that the protocol used is suitable for detecting 
endogenous levels of Bad in canine cells by immunohistochemistry and might, at least to 
some extent, detect variations in protein amounts. Therefore, the method was considered 
adequate for further analyses of the expression patterns of Bad in non-neoplastic canine 
tissues and canine lymphomas. 
 
 
 
 
Figure S2. Immunohistochemical validation of anti-Bad antibody 1541-1 using cultured UV-irradiated 
canine keratinocytes. Figure S2a. Non-irradiated control at 30 min; Figure S2b. Cells 30 min post-
irradiation (p.i.); Figure S2c. 4 h p.i.; Figure S2d. 8 h p.i.; Figure S2e. 12 h p.i.; Figure S2f. 24 h p.i.; 
cytoplasmic signal intensity appears to slightly increase 30 min and 4 h after UV-irradiation and to 
continuously decrease thereafter, especially in apoptotic cells; marked signs of apoptosis are present 
from 8 h post-irradiation and onwards. Detection with Omni-UltraMap, hematoxylin counterstain. 
(Continued next page.) 
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(Figure legend continued:) Figure S3. Western blot validation of anti-Bad antibody 1541-1 using 
cultured UV-irradiated canine keratinocytes. Figure S3a. Upper panel: immunoblot using antibody 
1541-1; lower panel: same membrane blotted with anti-β-actin antibody; Figure S3b. Intensities of 
Bad labeling of Figure S3a, upper panel, normalized to labeling for β-actin in Figure S3a, lower panel; 
lane and column labels indicate time after treatment (NI, grey color = non-irradiated; UV, brown color = 
UV-irradiated); a band doublet of 21 and 18 kDa corresponding to Bad is present in all lanes, 
quantitative analysis indicates an initial increase, then a decrease of Bad protein from 8 h p.i. and 
onwards.  
 
 
Material and methods 
Recombinant proteins. cDNAs of canine Bcl-2 family proteins (Bcl-xL, Bcl-w, Mcl-1, Bak, Bax, 
Noxa, Bad) and of other canine proteins involved in apoptosis (p53, caspase-3, caspase-8, 
caspase-9) cloned into a pGEX4t2 vector (Invitrogen, Carlsbad CA, USA) were available 
from either a previous study6 or from a concomitant study (manuscript in preparation). 
GenBank accession numbers of previously unreported canine sequences are as follows: Bcl-
w: AAZ22484, Bak: AAY19401, Noxa: ABE02691, Bad: AAZ32936, Caspase-8: ABB02414, 
Caspase-9: AAZ22485. The plasmids were transformed into BL21 Star E. coli (Invitrogen) 
and the proteins were expressed as Glutathione-S-Transferase (GST) fusion proteins by 
isopropyl-beta-D-thiogalactopyranoside (IPTG, Sigma-Aldrich, Buchs, Switzerland) induction 
for 2.5 h as previously described.6 For immunohistochemical studies, induced bacterial 
cultures (100 ml) were centrifuged at 4000 g for 10 min at 4 °C, resuspended in 4% neutral 
buffered formaldehyde and fixed for 24 h at room temperature. Subsequently, the bacteria 
were pelleted and embedded in paraffin wax using the Cytoblock system (Thermo Shandon, 
Pittsburgh, PA, USA).6 A microarray with one 0.6 mm core of each protein-expressing 
bacterial pellet was assembled by means of a manual tissue arrayer and denominated 
bacterial pellet array (Beecher Instruments, Sun Prairie, USA). For western blot analysis, 
GST-Bad, GST-Noxa, GST-p53 and GST only were expressed in 500 ml cultures of BL21 
Star E. coli bacteria after induction with 1mM IPTG and purified using glutathione 4B 
Sepharose beads (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) as previously 
described14 and stored at -20 °C until further processing.  
 
UV-irradiated canine keratinocytes. Canine normal keratinocytes (Bskin, kindly donated by E. 
Müller and MM. Suter, Bern, Switzerland) were cultured at 37 °C and v/v 5% CO2 in 
Dulbecco’s Modified Eagles medium supplemented with non-essential amino acids 1%, 
sodium pyruvate 1%, penicillin/streptomycin 1%, glutamax 1% (all reagents from Gibco BRL 
Life Sciences, Basel, Switzerland) and fetal calf serum 15% (BioConcept Ltd., Allschwil, 
Switzerland). The cells were irradiated with 100 mJ UV light using an UV crosslinker with an 
emission peak at 254 nm (Hoefer UVC 500, Hoefer Inc., Holliston MA, USA) after replacing 
the medium with PBS. Irradiated and non-irradiated control cells were covered with cell 
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culture medium again, cultured further and harvested 30 min, 4 h, 8 h, 12 h and 24 h after 
irradiation. Non-irradiated control cells were collected at time points corresponding to 30 min 
and 12 h after irradiation. Cells for each sampling time were cultured in duplicate in 75 cm2 
cell culture dishes. For immunohistochemical assays, the cells were pelleted, fixed in 
buffered 4% formaldehyde for 24 h and embedded in paraffin wax as previously described.6 
For western blot analysis, the cells were lysed as described for CL-1 cells in the main 
manuscript, and the lysate was stored at 4 °C until further processing. 
 
Antibodies against Bad. Based on the canine Bad protein sequence deduced from our cDNA 
clone (GenBank accession number AAZ32936), five commercially available antibodies raised 
against human or murine Bad immunogens displaying the highest possible sequence 
homology (where appropriate) with the canine orthologue were identified. They are listed in 
Table S1 together with the relevant information including the tests in which they were used 
and the respective dilutions. Selling of antibody JM-3030-100 (MBL International, Woburn 
MA, USA) was discontinued by the manufacturer during this study. 
 
 
Table S1. Commercially available antibodies used in this study. 
 
 
 
Western Blots. Bacterially expressed, beads-bound GST fusion proteins were diluted with 
SDS loading buffer and processed as indicated in the main manuscript. Immunoblots were 
done using the antibodies listed in Table S1 as indicated in the main manuscript with the 
difference that a horseradish peroxidase-conjugated polyclonal goat-anti-mouse-HRP 
antibody (Geno Technologies, St. Louis MO, USA) was applied where appropriate. For each 
keratinocyte lysate sample 16 µg were loaded with 4x SDS loading buffer and processed 
using antibody 1541-1 and JM-3030-100 (Table S1) and anti-β-actin monoclonal mouse 
antibody (ab8227, Abcam, Cambridge, UK) in a 1:3000 dilution. For negative control 1% BSA 
in TBST was used instead of the primary antibody where appropriate. To calculate the ratio 
between Bad and β-actin the corresponding bands were scanned and the intensities of 
individual bands measured using the ImageJ program (http://rsb.info.nih.gov/ij/index.html). 
Bead%bound*
GST%proteins
Cell*culture*/*
tissue*lysates
Bacterial*
pellets
Cell*pellets*/*
tissue*arrays
1541%1 Epitomics,*Burlingame*CA,*USA mAba*rabbit
aab*1%20*of*human*
Bad
NKc 1:50*000 1:5000 1:1000 1:1500
JM%3030%100d
MBL*International,*Woburn*MA,*
USA pAb
e*rabbit
full%length*murine*
Bad
0.1mg/ml 1:100 1:75 1:100 NDf
NBP1%19451
Novus*Biologicals,*Cambridge,*
UK
pAb*rabbit
aa*110%160*of*
human*Bad
1.0*mg/ml 1:100*%*1:750 ND 1:20*%*1:100 ND
sc%8044
Santa*Cruz*Biotechnology*Inc,*
Santa*Cruz,*USA
mAb*mouse
full%length*human*
Bad
0.2mg/ml 1:100*%*1:500 ND 1:20*%*1:1000 ND
HPA*028185
Sigma*Aldrich*Co.*LLC,*St.*Louis*
MO,*USA
pAb*rabbit
aa*12%87*of*human*
Bad
0.1mg/ml 1:100*%*1:250 1:100 1:20*%*1:100 ND
a*amino*acid;*b*monoclonal*antibody;* c*not*known;*d*Manufacturer*discontinued*selling*of*this*product*during*this*study; *e*polyclonal*antibody;*f*not*done
Western*Blot Immunohistochemistry
Dilutions*in*indicated*test*with*indicated*materials
Catalogue*no. Manufacturer Antibody*
type
Immunogen Antibody*
concentration
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Immunohistochemistry using anti-Bad antibodies. The whole immunohistochemical 
procedure including the antigen retrieval was run in a Discovery XT autostainer (Ventana 
Medical Systems, Inc., Tucson AZ, USA) according to the manufacturer’s instructions. The 
bacterial pellet array sections were pretreated either with citrate buffer (pH 6.0, CC2 cell 
conditioning solution (950-123), Ventana) with the CC2 standard program (4x 8 min 98 °C), 
with Tris-based buffer (pH 8.4, CC1 cell conditioning solution (950-124), Ventana) with the 
CC1 standard program (4x 8 min 98 °C) or with proteinase 1 (Ventana) for 8 min. A fourth 
sample underwent no pretreatment. The antibody selection steps were carried out using all 
five commercially available antibodies, which were tested with all pretreatments at different 
dilutions varying from 1:20 to 1:1000 (Table S1). Incubation conditions with primary antibody 
were 1 h at 37 °C. A universal secondary antibody and the Omni-UltraMap and RedMap 
Detection Kits (Ventana) were used. With bacterial pellet arrays, an antibody was considered 
specific if the labeling of the core containing bacteria expressing GST-Bad was clearly 
distinguishable from that of all remaining cores. 
 
  
 25 
Danksagung 
 
An dieser Stelle möchte ich mich bei allen bedanken, die zum Gelingen dieser Arbeit 
beigetragen haben: 
 
Franco Guscetti für die Vergabe des spannenden Themas und die fachliche Betreuung. 
Martina Croci und Lloyd Vaughan für die Unterstützung im Labor. 
Sabina Wunderlin für ihre unverzichtbare Hilfe bei der Immunhistochemie. 
 
Ein sehr grosser Dank gilt meinen Eltern, die mich immer unterstützt haben - insbesondere 
meinem Vater Max Dettwiler. 
 
Und ein besonderer Dank geht an meine Freundin Laura Laschinger - einfach für alles. 
 26 
  
 27 
Curriculum vitae 
 
Name, Vornamen:   Dettwiler Martina Andrea 
 
Geburtsdatum:  11.08.1981 
 
Geburtsort:   Basel BS 
 
Nationalität   Schweiz 
 
Heimatort   Reigoldswil BL 
 
08/1988 – 06/1993  Primarschule Birsfelden, Schweiz 
 
08/1993 – 06/1997  Progymnasium Birsfelden, Schweiz 
 
08/1997 – 12/2000  Gymnasium Muttenz, Schweiz 
 
19.12.2000 Matura Typus B (Latein), Gymnasium Muttenz, Schweiz 
 
09/2001 – 11/2006 Studium Veterinärmedizin, Universität Zürich, Schweiz 
 
03.11.2006 Eidgenössisches Diplom Veterinärmedizin, Universität Zürich, 
Schweiz 
 
05/2007 – 10/2009 Assistenztierärztin Gemischtpraxis, Tierarztpraxis Dres. Fürer 
und Spühler, Frauenfeld, Schweiz 
 
10/2007 – 12/2009 Assistenztierärztin Gemischtpraxis, Tierarztpraxis Dres. Schär 
und Wick, Affeltrangen, Schweiz 
 
01/2010 – 02/2013  Anfertigung der Dissertation 
unter Leitung von Prof. Dr. med. vet. Franco Guscetti 
am Institut für Veterinärpathologie der Vetsuisse Fakultät Zürich 
Direktor: Prof. Dr. med. vet. Andreas Pospischil 
 
 
 
 
 
 
 
Zürich, 03.02.2013 
